Načítá se...
Lysophosphatidic acid and its receptors LPA(1) and LPA(3) mediate paclitaxel-induced neuropathic pain in mice
BACKGROUND: Paclitaxel, which is widely used for the treatment of solid tumors, causes neuropathic pain via poorly understood mechanisms. Previously, we have demonstrated that lysophosphatidic acid (LPA) and its receptors (LPA(1) and LPA(3)) are required for the initiation of peripheral nerve injury...
Uloženo v:
| Vydáno v: | Mol Pain |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4246549/ https://ncbi.nlm.nih.gov/pubmed/25411045 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1744-8069-10-71 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|